Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies-Reference-Cited by-同舟云学术

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Published:2015-03-18 Issue:3 Volume:33 Page:652-663
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Smith David C.,Kalebic Thea,Infante Jeffrey R.,Siu Lillian L.,Sullivan Daniel,Vlahovic Gordana,Kauh John S.,Gao Feng,Berger Allison J.,Tirrell Stephen,Gupta Neeraj,Di Bacco Alessandra,Berg Deborah,Liu Guohui,Lin Jianchang,Hui Ai-Min,Thompson John A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0230-x.pdf

Reference38 articles.

1. Ciechanover A, Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A 95(6):2727–2730

2. Hershko A (2005) Early work on the ubiquitin proteasome system, an interview with Avram Hershko. Interview by CDD. Cell Death Differ 12(9):1158–1161

3. McBride A, Ryan PY (2013) Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 13(3):339–358

4. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120(5):947–959

5. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649–1657

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer;Oral Oncology Reports;2024-09

2. Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization;npj Precision Oncology;2024-05-18

3. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts;Experimental Hematology;2024-04

4. Inhibitory effort of MLN2238 on basal-like breast cancer: An investigation based on the gene set enrichment analysis;Cellular and Molecular Biology;2023-07-31

5. HPV16 status predicts potential protein biomarkers and therapeutics in head and neck squamous cell carcinoma;Virology;2023-05